Targeting vulnerabilities of aneuploid cells for cancer therapy
Trends in Cancer · 2025-07 · 11 (7) · 642-664
DOI: 10.1016/j.trecan.2025.04.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Cancer, 2025-07. Verfasst von Johanna Zerbib und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Aneuploidy, Neoplasms, Molecular Targeted Therapy, Antineoplastic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 262 Literaturangaben. Gefördert von: Israel Science Foundation, United States-Israel Binational Science Foundation, European Research Council.
Abstract (Originalsprache)
Aneuploidy is a common feature of cancer that drives tumor evolution, but it also creates cellular vulnerabilities that might be exploited therapeutically. Recent advances in genomic technologies and experimental models have uncovered diverse cellular consequences of aneuploidy, revealing dependencies on mitotic regulation, DNA replication and repair, proteostasis, metabolism, and immune interactions. Harnessing aneuploidy for precision oncology requires the combination of genomic, functional, and clinical studies that will enable translation of our improved understanding of aneuploidy to targeted therapies. In this review we discuss approaches to targeting both highly aneuploid cells and cells with specific common aneuploidies, summarize the biological underpinning of these aneuploidy-induced vulnerabilities, and explore their therapeutic implications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. Electronic address: ubendavid@tauex.tau.ac.il.
Förderung
- Israel Science Foundation
- United States-Israel Binational Science Foundation
- European Research Council
- United States - Israel Binational Science Foundation
- HORIZON EUROPE European Research Council
- Israel Cancer Research Fund
Zitieren
APA
Zerbib, J., Bloomberg, A., & Ben-David, U. (2025). Targeting vulnerabilities of aneuploid cells for cancer therapy. Trends in Cancer, 11(7), 642-664. https://doi.org/10.1016/j.trecan.2025.04.005
Vancouver
Zerbib J, Bloomberg A, Ben-David U. Targeting vulnerabilities of aneuploid cells for cancer therapy. Trends in Cancer. 2025;11(7):642-664. doi:10.1016/j.trecan.2025.04.005
BibTeX
@article{Zerbib2025,
author = {Zerbib, Johanna and Bloomberg, Amit and Ben-David, Uri},
title = {Targeting vulnerabilities of aneuploid cells for cancer therapy},
journal = {Trends in Cancer},
year = {2025},
volume = {11},
number = {7},
pages = {642--664},
doi = {10.1016/j.trecan.2025.04.005}
}
EUVIMED